
FDA Publishes Guidance on Drug Effectiveness
The agency published guidance to help with the development of enrichment strategist for clinical investigations of drug and biologic effectiveness.
On March 14, 2019, FDA published
The guidance defines enrichment as “the prospective use of any patient characteristic to select a study population in which detection of a drug effect (if one is in fact present) is more likely than it would be in an unselected population.” The document discusses precision medicine and the interpretation of studies. Specifically, the guidance addresses decreasing variability, identifying high-risk patients and more responsive patients, and regulatory issues.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.